Navigation Links
Oncogenic signatures mapped in TCGA a guide for the development of personalized therapy
Date:9/27/2013

New York, September 27, 2013 -- Clinical trial design for new cancer therapies has historically been focused on the tissue of origin of a tumor, but a paper from researchers at Memorial Sloan-Kettering Cancer Center published on September 26 in Nature Genetics supports a new approach: one based on the genomic signature of a tumor rather than the tissue of origin in the body.

It is well known that the emergence of cancer is a multi-step process, but because of the efforts of The Cancer Genome Atlas (TCGA), funded by the US National Institutes of Health, and other large-scale cancer genomics efforts, for the first time this process can be viewed in exquisite molecular detail, mapping mutations and other molecular events affecting any of the 20,000 genes in a human cell.

Now, two major hypotheses have been confirmed from the genomic analysis of more than 3000 samples from 12 different tumor types: a limited number of specific genetic events appear to cause most tumor subtypes and tumors can be grouped by the oncogenic signatures they contain, no matter what the tissue of origin. That these oncogenic signatures are largely independent of the particular tissue in which the cancer arises indicates that certain drug combinations may be beneficial for select patients with different types of cancer.

"In future clinical trials, we envision that patients with a certain type of endometrial cancer, for example, may be enrolled in the same trial as patients with a subtype of colorectal cancer, and that patient selection for clinical trials can be guided by cancer genomics profiling in the clinic," stated Chris Sander, one of the principal investigators of Memorial Sloan-Kettering's Genome Data Analysis Center. "This work is intended to help in the design of such trials and the development of more-personalized cancer therapies."

The ability to reveal sets of cancer-causing events in molecular detail is based on three major technical
'/>"/>

Contact: Caitlin Hool
hoolc@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Biosignatures distinguish between tuberculosis and sarcoidosis
2. Epigenetic signatures direct the repair potential of reprogrammed cells
3. Finally mapped: The brain region that distinguishes bits from bounty
4. 100+ million mapped (and growing) records of nearly every living US species
5. Genes behind obesity mapped in large-scale study
6. Sea lamprey genome mapped with help from scientists at OU
7. Rain Man-like brains mapped at UCSF
8. Stoneflies mapped across Ohio, with implications for water quality and nature conservation
9. Signal gradients in 3-D guide stem cell behavior
10. Medboxs Marijuana Dispensing System Assists Operators in Complying with Federal Governments New Canna-Business Guidelines
11. Feline behavior experts release guidelines to improve the welfare of cats
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... Conn. , Jan. 26, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... new corporate website ( http://www.nxt-id.com/ ) as part of ... smart wallet. The Company launched its new consumer website ... Gino Pereira , CEO of NXT-ID said, "Our new ...
(Date:2/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ... "Global Biometrics Market (2014-2020): Market Forecast By Technologies, ... to their offering. , In ... is anticipated to overtake North America ... spending towards IT security, government biometric based projects ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... 2010 Fido,s wet licks might hold more than love. ... for rare cancers and other diseases in both dogs and ... the Van Andel Research Institute (VARI) have created the Canine ... cancers in dogs to better understand why both pets and ...
... Abstract:, The transfer of scientific data has emerged as ... size and demand as open access sharing increases. Current ... large files and can cause long transfer times. In ... open access sharing of scientific data and uses the ...
... different environments don,t necessarily also have different ecological ... investigating the accuracy of current statistical tests that ... in environmental requirements. In a new study ... a model simulating the distributions of two imaginary ...
Cached Biology News:Slobbery kisses from 'man's best friend' aid cancer research 2Slobbery kisses from 'man's best friend' aid cancer research 3Slobbery kisses from 'man's best friend' aid cancer research 4Slobbery kisses from 'man's best friend' aid cancer research 5BioTorrents: An OA file sharing service and more 2BioTorrents: An OA file sharing service and more 3BioTorrents: An OA file sharing service and more 4BioTorrents: An OA file sharing service and more 5Species distribution models can exaggerate differences in environmental requirements 2
(Date:3/4/2015)... 2015 The UPMC Center for Health Security ... the Emerging Leaders in Biosecurity Initiative (ELBI). As part ... field of biosecurity, UPMC has selected 28 US and ... of backgrounds, including biological science, medicine, policy, the military, ... "With the vision and support of the Defense Threat ...
(Date:3/4/2015)... 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") ... collaborative research program with Emerald Logic, a ... Evolution Technology (FACET), Emerald Logic analyzed Resverlogix,s ... from each of 798 patients who participated ... ASSERT, SUSTAIN and ASSURE. The objective of ...
(Date:3/4/2015)... Korea , March 4, 2015 Vegalab ... company, in August of last year. As part of ... Kyung Bon Koo continuing his role as CEO ... President of Vegalab S.A., will work alongside Koo and ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 Koo ...
(Date:3/3/2015)... DIEGO and TORONTO, March 3, 2015 /PRNewswire/ - Aptose ... developing new therapeutics and molecular diagnostics that target the ... the quarter and seventh-month period ended December 31, 2014. ... its fiscal year end from May 31 to December ... we are reporting today are for the quarter and ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... Annual European Meeting to be Held In Paris, ... (Nasdaq: PHST ), a leading provider of ... drug,development, today announced that it will host its ... on May 28,and 29, 2008 at the Hotel ...
... 22 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) will ... New York on Wednesday, May 28, 2008 at 9:45 ... Executive Director, Medical Affairs of,Amylin Pharmaceuticals, will be providing ... session will be webcast, and a,recording will be made ...
... N.C., May 22 Pharmaceutical and biotech,companies increasingly are ... functions. This benchmarking study will help R&D,Quality Assurance executives ... QA staff resources so that they have the most ... in regards to the FDA,s Risk-Bases method for ...
Cached Biology Technology:Pharsight Hosts European PKS User Meeting 2Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutical Industry 2
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
... --- a cocktail of 3 siRNAs specifically ... our most popular product. The siTrio reagent ... of your target gene when used under ... and confirmation of optimal transfection with one ...
... with 96 x 0.2 ml reaction module ... applications. It is equipped with an interchangeable ... is compatible with optical modules for real-time ... by algorithm, block, or in-sample probe. It ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
Biology Products: